Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16455152 | 0.93 | KDM1A (0.58) | KDM1A | |
| SCHEMBL22856663 | 0.93 | KDM1A (0.58) | KDM1A | |
| SCHEMBL17981464 | 0.89 | KDM1A (0.58) | KDM1A | |
| SCHEMBL16448251 | 0.87 | KDM1A (0.61) | KDM1A | |
| SCHEMBL26148455 | 0.86 | KDM1A (0.46) | KDM1A | |
| SCHEMBL16455065 | 0.85 | KDM1A (0.60) | KDM1A | |
| SCHEMBL16455064 | 0.85 | KDM1A (0.60) | KDM1A | |
| SCHEMBL16455151 | 0.84 | KDM1A (0.59) | KDM1A | |
| SCHEMBL16455070 | 0.84 | KDM1A (0.56) | KDM1A | |
| SCHEMBL22856674 | 0.84 | KDM1A (0.59) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334873-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170334873-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334873-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | KDM1A 2/4885CYP2D6 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.